Why selling to Novartis made sense for Mariana - BioPharma Dive

May 3, 2024 · Novartis has additional radiopharmaceutical facilities in New Jersey, Italy and Spain, and is planning to open sites in Japan and China. Mariana has its own manufacturing …

CouponFollow Extension

$1
OFF

BioPharma Dive On LinkedIn: Why Selling To Novartis Made Sense …

20 hours ago

Conversations at this year's J.P. Morgan Healthcare Conference led to a $1 billion buyout that Mariana's CEO described as a "perfect marriage." Why selling to Novartis made sense for …

linkedin.com

$1
OFF

Novartis Agrees To Acquire Mariana Oncology For $1 Billion, Gains …

20 hours ago

May 3, 2024 · “This acquisition brings to Novartis phenomenal talent and new capabilities in RLT research that complement our wide-ranging internal efforts to explore novel isotopes, …

biopharminternational.com

$1
OFF

Novartis Buys Mariana Oncology In $1B Acquisition, Bolsters

20 hours ago

May 2, 2024 · Novartis pushed deeper into radioligand therapy Thursday, announcing a $1 billion buyout that will give it control of Mariana Oncology ’s preclinical cancer pipeline and clinical …

biospace.com

$1.75
OFF

Novartis To Buy Mariana Oncology For Up To $1.75 Billion In Boost …

20 hours ago

May 2, 2024 · Novartis agreed to acquire U.S. biotechnology company Mariana Oncology for up to $1.75 billion, in a deal that bolsters its radioligand therapy pipeline and efforts to develop …

morningstar.com

$1
OFF

Mariana Oncology To Be Acquired By Novartis For $1 Billion …

20 hours ago

May 2, 2024 · The Life Sciences team advised Mariana Oncology on its acquisition by Novartis for $1 billion upfront and up to $750 million in potential milestone payments. The acquisition …

goodwinlaw.com

$1
OFF

Novartis Extends Its Reach In Radiopharmaceuticals With $1B …

20 hours ago

May 2, 2024 · Novartis’s two commercialized radiopharmaceuticals are from acquisitions: Lutathera came in 2017 followed by Pluvicto in 2018. The Swiss pharma giant’s purchase of …

medcitynews.com

$1
OFF

Novartis Wagers More Than $1B On Gene Therapies For The Nervous …

20 hours ago

Nov 21, 2024 · DTx was one in a series of smaller-scale purchases Novartis made over the past couple years. The company snagged the radiopharmaceutical developer Mariana Oncology for …

biopharmadive.com

$1
OFF

Novartis Extends Radiopharma Plans With $1 Billion Acquisition

20 hours ago

May 2, 2024 · Novartis is paying $1 billion upfront and up to an additional $750 million if certain milestones are met to acquire startup Mariana Oncology, the latter company announced …

statnews.com

$1
OFF

Novartis Makes A $1B Radiopharma Deal, Buying Mariana Oncology

20 hours ago

May 2, 2024 · Novartis will pay $1 billion upfront to acquire radiopharmaceutical startup Mariana Oncology, just eight months after the preclinical biotech company disclosed a $175 million …

endpts.com

FAQs about Why selling to Novartis made sense for Mariana - BioPharma Dive Coupon?

Will Novartis buy Mariana oncology?

With much still to discover in the massive world of radiopharmaceuticals, Novartis will take a deep dive into the unknown with Mariana Oncology in a $1 billion upfront acquisition. ...

How much money will Mariana receive from Novartis?

Under the deal, Mariana will receive $1bn and up to $750m in additional milestone payments from Novartis. Novartis will inherit Mariana’s lead asset MC-339, a radioligand therapy (RLT) designed to target small cell lung cancer. Credit: JHVEPhoto via Shutterstock. ...

Is Novartis a top player in the radiopharmaceutical space?

Novartis is firming its role as the top player in the radiopharmaceutical space with the acquisition of Mariana Oncology for $1bn upfront, and up to $750m in additional milestone-based payments. Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. ...

Should a biotech choose Novartis or Mariana?

While Mariana had a neatly planned pipeline, Read said a biotech always has to pick and choose the programs carefully based on financing, head count and other factors. With the weight of Novartis, the biotech can take a broader range of ideas forward and ultimately reach more patients than it ever could have alone. ...

What's the difference between Novartis and Mariana?

Novartis’ Pluvicto and Lutathera are approved for prostate cancer and neuroendocrine tumors, respectively, while Mariana’s pipeline tackles a wider range of tumor types and targets. While peers like Lilly have been focused on bulking up the manufacturing side of the business, Novartis’ interest in Mariana was more around innovation. ...

Who bought Mariana pharmaceuticals?

The Swiss pharma giant’s purchase of Mariana continues a newer streak of radiopharmaceuticals dealmaking by other big pharma layers. Last year, Eli Lilly entered the radiopharmaceuticals space with the $1.4 billion acquisition of Point Biopharma. Bristol Myers Squibb soon followed with its $4.1 billion acquisition of RayzeBio. ...